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In an attempt to increase the life of cementless prostheses, an hydroxyapatite-coated 
implant which releases a bisphosphonate has been suggested as a drug-delivery system. 
Our 
 
in vitro
 
 study was designed to determine the maximum dose to which osteoblasts 
could be safely exposed.
Our findings demonstrated that zoledronate did not impair the proliferation of human 
osteoblasts when used at concentrations below 1 
 
µ
 
M
 
. Murine cells can be exposed to 
concentrations as high as 10 
 
µ
 
M
 
.
A concentration of 0.01% of titanium particles did not impair the proliferation of either 
cell line. Zoledronate affected the alkaline phosphatase activity of murine osteoblasts 
through a chelation phenomenon. The presence of titanium particles strongly decreased 
the alkaline phosphatase activity of murine osteoblasts. We did not detect any synergic 
effect of zoledronate and titanium particles on the behaviour of both human and murine 
osteoblasts.
 
The rate of failure of cementless implants can
exceed 30% at 15 years for patients younger
than 50 years of age.
 
1
 
 The main cause of fail-
ure is aseptic loosening after osteolysis caused
by stress shielding
 
2
 
 or by an inflammatory
reaction induced by wear particles or both.
 
3
 
 In
addition to improvement in the material and
wear properties of the implant, new therapy
using systemic treatment with bisphospho-
nates has been considered recently.
 
4
 
 However,
these drugs have important side-effects includ-
ing ulcers of the throat or stomach
 
5
 
 as well as
complicated pathology because of the poor
bioavailability of bisphosphonates.
 
6
 
 These dif-
ficulties could limit the use of bisphosphonate
therapy after total hip arthroplasty.
In order to avoid the problems of systemic
treatment implants could provide a local drug-
delivery system
 
7
 
 using a coating with a carrier,
such as hydroxyapatite combined with a bis-
phosphonate. The non-aminobisphosphonates
or the aminobisphosphonates could be used
 
8
 
since they have higher efficiency and a higher
bioavailability. They do not seem to impede the
process of bone-renewal and therefore main-
tain the strength of the bone  whereas the non-
aminobisphosphonates are thought to weaken
bone over time.
It is important to determine the concentra-
tions of drugs to which osteoblasts can be
safely exposed. The drug will be acting at the
interface between the bone and the implant
where metal debris is generated. These parti-
cles will be the principal particle population in
the months after implantation. It is therefore
important to establish whether the combina-
tion of metal particles and bisphosphonates
might impair the activity of osteoblasts.
 
In vitro
 
 studies quantifying the simul-
taneous effect of bisphosphonates and wear
particles are scarce. When considering only
bisphosphonates, it has been shown that 10
 
µ
 
M
 
 pamidronate represents the maximum con-
centration below which no negative effect is
observed either on proliferation or on the
activity of alkaline phosphatase (ALP) of
human fetal osteoblasts (hFOB).
 
9
 
 Alendronate,
another bisphosphonate, affected the viability
of human osteoblasts at concentrations of 100
 
µ
 
M
 
,
 
10
 
 but below this no adverse effects were
observed. It is of interest that bisphosphonates
can induce positive effects on osteoblasts, as
was shown with two different bisphospho-
nates (olpadronate and pamidronate), which
increased proliferation in osteoblasts derived
from calvaria and ROS 17/2.8 up to 0.1 
 
µ
 
M
 
.
 
11
 
Zoledronate is an aminobisphosphonate
which is 1000 times more potent than pamidr-
onate.
 
12
 
 Few studies have been performed to
evaluate the direct effect of zoledronate on
osteoblasts 
 
in vitro
 
.
 
13
 
 As Klein et al
 
14
 
 have
shown, different bisphosphonates induce dif-
 1158 B. PETER, P.-Y. ZAMBELLI, J. GUICHEUX, D. P. PIOLETTI
THE JOURNAL OF BONE AND JOINT SURGERY
 
ferent effects on bone. It is difficult to extrapolate the effect
of the concentration of one bisphosphonate to another.
Zoledronate stimulated proliferation of hFOB by up to
30% after 72 hours for concentrations ranging from 0.01
 
µ
 
M
 
 to 10 
 
µ
 
M
 
.
 
15
 
 Longer term studies showed, however, that
cell proliferation was finally reduced by 40% after seven
days. The same range of concentration of zoledronate stim-
ulated ALP activity by 30%. By contrast, it has been shown
that 10 
 
µ
 
M
 
 zoledronate decreased proliferation of hFOB as
compared with a control series.
 
9
 
 Viereck et al
 
16
 
 demon-
strated that the maximum osteoprotegerin (OPG) protein
secretion in human primary osteoblasts was obtained with
concentrations of zoledronate between 0.001 
 
µ
 
M
 
 and 1 
 
µ
 
M
 
.
A concentration of zoledronate of 0.01 
 
µ
 
M
 
 increased ALP
activity by a factor of two to four in primary human osteo-
blasts. These findings show some discrepancy in the action
of zoledronate on osteoblasts.
Wear particles have recently been shown to influence the
behaviour of osteoblasts 
 
in vitro
 
17-20
 
 possibly resulting in
decreased peri-implant bone formation. Lohmann et al
 
21
 
showed that particles were found intracellularly, primarily
in the cytoplasm and that this led to extensive deformation
and damage to organelles. Particles also inhibited the func-
tion of osteoblast as shown by a reduction in the develop-
ment of mineralised nodules and in the area of ALP-positive
colonies.
 
22
 
Few studies have evaluated the simultaneous effect of
bisphosphonates and particles. One showed that by mixing
a bisphosphonate with bone cement, it was possible to
inhibit resorption caused by polymethylmethacrylate parti-
cles.
 
23
 
 Hyvonen and Kowolik
 
24
 
 developed a system of bis-
phosphonate delivery by combining hydroxyapatite
particles and clodronate. The phagocytic activity of macro-
phages was reduced by the presence of clodronate after
only 48 hours. These results support the concept of devel-
oping an orthopaedic implant which acts as a delivery sys-
tem for bisphosphonates.
Our aim was to determine 
 
in vitro
 
 the local concentra-
tions of zoledronate which could be used without a nega-
tive effect on the proliferation of osteoblasts and ALP
activity and also to verify that there was no synergic nega-
tive effect when culturing these cells simultaneously with
bisphosphonate and particles.
 
Materials and Methods
 
Cell lines. 
 
In order to evaluate in an 
 
in vitro
 
 model the local
effect of different zoledronate concentrations of murine
MC3T3-E1 cells
 
25
 
 and human MG-63 cells
 
18
 
 was used.
 
Cell culture. 
 
The culture medium for MG-63 cells was com-
posed of Dulbecco’s minimum essential medium (DMEM)
(Sigma-Aldrich, St Louis, Missouri), 10% fetal bovine
serum (Sigma-Aldrich), 1% antibiotic (penicillin, strepto-
mycin) and fungicide (amphotericin B) (Invitrogen, Carls-
bad, California). That for MC3T3-E1 cells consisted of 
 
α
 
-
MEM (BioConcept, Allschwill, Switzerland), 2.2 g/l of
NaHCO
 
3
 
 (Sigma-Aldrich), 0.5% essential amino acids
(BioConcept), 10% fetal bovine serum (Sigma-Aldrich),
1% L-glutamine (BioWittaker, Rutherford, New Jersey), 50
 
µ
 
g/ml of L-ascorbic acid (Sigma-Aldrich) and 10 m
 
M
 
 
 
β
 
-
glycerophosphate (Sigma-Aldrich).
 
26
 
 Ethylenediaminetetra
acetic acid (EDTA) (Sigma-Aldrich) at a concentration of
0.01 
 
µ
 
M
 
 was used to control the effect of chelation on the
cells since the decrease in Ca
 
+2
 
 ions has an influence on ALP
activity.
 
27
 
 Zoledronate (1-hydroxy-2-(1H-imidazole-1-yl)
ethylidene) 1-bisphosphonic acid disodium salt) was sup-
plied by Novartis Pharmaceuticals AG (Basel, Switzerland).
It was dissolved in sterile nanopure water and added to the
culture at the first medium exchange.
The cells were collected by trypsinisation and were
seeded at a density of 5000 cells per well on 96-well plates.
They were incubated at 37˚C, 5% CO
 
2
 
 and 100% humid-
ity. The cell and particle system had been optimised in pre-
vious studies.
 
18,28,29
 
 After 24 hours, the medium was
replaced with 200 
 
µ
 
l of medium containing zoledronate in
concentrations of 0, 0.1, 1.0, 10.0 and 50.0 
 
µ
 
M
 
. Half of all
the wells contained titanium particles. Half of the medium
was changed every three days for fresh culture medium not
containing any zoledronate or particles. Proliferation, ALP
activity and total protein were measured after four hours
and on days 2, 7, 14, 21 and 28. Every condition was tested
in triplicate and in three temporally separated culture series.
 
Titanium particles. 
 
Commercially pure titanium particles
were purchased from Johnson & Matthey Company
(Karlsruhe, Germany). The distribution of particle size was
performed by laser diffraction using Malvern MasterSizer
equipment (Malvern Instruments Ltd, Malvern, UK). The
mean particle size was 4.5 
 
µ
 
M
 
 and the surface area was 0.5
m
 
2
 
/mg. The particles, autoclaved at 135˚C for 15 minutes,
were mixed with the culture medium under sterile condi-
tions. Based on a particle-weight-to-medium-volume ratio,
a concentration of 0.01% titanium particles was prepared.
There were approximately 60 000 particles in 1 ml of par-
ticle suspension of 0.01%. The titanium particle suspen-
sions were sonicated for 30 minutes in sealed sterile
containers before being added to the cell culture. The
threshold for titanium particles above which proliferation
decreased and below which proliferation was the same as
the control was 0.01%.
 
18
 
 This concentration was used to
quantify a hypothetical synergic effect of zoledronate and
titanium particles on the behaviour of osteoblasts.
 
Proliferation. 
 
At every time point, the medium was com-
pletely removed by careful pipetting and then replaced with
100 
 
µ
 
l of fresh medium. In parallel, three wells with fresh
medium but without cells were prepared and used as
blanks. A proliferation array was performed by adding 10
 
µ
 
l of CellTiter 96 Aqueous One (Promega, Madison, Wis-
consin) to every well. The resulting solution was then incu-
bated for one hour at 37˚C, 5%CO
 
2
 
 and 100% humidity.
From each well 100 
 
µ
 
l were then transferred in a new 96-
well plate and the absorbance measured at 490 nm in a Vic-
tor plate reader (Wallac, Turku, Finland). To calculate the
proliferation, the formula given by Promega was used. The
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proliferation was normalised by dividing the proliferation
of every condition at every time point by the proliferation
of the cells not exposed either to zoledronate or to particles
at the same time point.
 
Total protein. 
 
At every time point, the medium was com-
pletely removed by careful pipetting. All the wells were
rinsed twice with phosphate-buffered saline. The plates
were stored at -80˚C until being processed. To ensure
proper cell lysing 100 
 
µ
 
l of 1% Triton-X aq were added and
pipetted several times. Using the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, California) and comply-
ing with the manufacturer’s instructions, the total protein
content was measured for every well.
The calibration was made using six dilutions in triplicate
of a fetal bovine albumin solution contained in the Bio-Rad
Protein Assay II (Bio-Rad Laboratories).
 
ALP. 
 
To determine if differentiation of the cells had taken
place, the ALP activity was quantified since it is one of the
earliest markers of the differentiation of osteoblasts.
 
30
 
Since MG-63 cells are known to produce very low amounts
of ALP, only the ALP activity of MC3T3-E1 cells was mea-
sured. The cells were located on the same plates as the cells
used for the total protein assay and followed the same treat-
ment; 2 
 
µ
 
l of lysate were added to 100 
 
µ
 
l of p-nitrol tablets
as substrate (Sigma-Aldrich). The ALP activity was given by
the slope of the absorption 
 
vs
 
 time curve (see Sigma, Pro-
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cedure N245) and was normalised for the total protein con-
tent which was determined as described above and
expressed as nM p-nitrophenyl phosphate (PNP)/min/mg
protein.
 
Statistical analysis. 
 
One-way ANOVA and Student’s 
 
t
 
-test
were used to determine the statistical significance of the dif-
ferences in the results. A probability value of p < 0.05 was
considered to be statistically significant.
 
Results
 
Proliferation. 
 
Figure 1 shows the evolution of proliferation
of MC3T3-E1 cells exposed to various concentrations of
zoledronate and titanium particles. Four hours after seed-
ing proliferation was the same for all the different condi-
tions (Fig. 1a). After two days, it slightly decreased for the
cells treated with 0.1 
 
µ
 
M
 
 and 1 
 
µ
 
M
 
 zoledronate (Fig. 1b).
This finding was independent of the presence of titanium
particles. The exposure of the cells to 10 
 
µ
 
M
 
 and 50 
 
µ
 
M
 
zoledronate significantly decreased the proliferation of cells
(p < 0.001). After seven days, concentrations of zoledronate
of 0.1 
 
µ
 
M
 
 and 1 
 
µ
 
M
 
 only slightly decreased the proliferation
(Fig. 1c). When the MC3T3-E1 cells were exposed simulta-
neously to 10 
 
µ
 
M
 
 zoledronate and titanium particles, the
proliferation became close to the level of that measured on
cells treated with the lower doses. When 10 
 
µ
 
M
 
 zoledronate
alone was present, proliferation decreased, but was statisti-
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cally not significant. At a concentration of 50 
 
µ
 
M
 
 it stopped
completely and was inhibited for all subsequent time
points. After 14 days, all the zoledronate-treated cells,
apart from those treated with 50 
 
µ
 
M
 
, were at the same level
as the control cells. This profile remained the same after
exposure to zoledronate for 21 and 28 days (Figs 1d to 1f).
Figure 2 shows the evolution of the proliferation for
MG-63 cells exposed to various concentrations of zole-
dronate and titanium particles. During the first 48 hours,
no difference in proliferation was seen as a function of
treatment with zoledronate or the presence of titanium par-
ticles (Figs 2a and 2b). At 7 and 14 days, the concentra-
tions of 0.1 
 
µ
 
M
 
 and 1 µM of zoledronate gave the same
proliferation as the control (Figs 2c and 2d). At concentra-
tions of 10 µM and 50 µM, proliferation is strongly
decreased in a dose-dependent manner (p < 0.0001). This
profile was repeated at incubation for 21 and 28 days (Figs
2e and 2f).
EDTA did not show any influence on proliferation for
both cell lines (data not shown). No synergic effect of
zoledronate and particles was detected on the proliferation
of osteoblasts (p < 0.08).
Light microscopy showed that at higher concentrations
of zoledronate the osteoblasts were rounded but still
attached. At lower concentrations, they did not show any
morphological differences as compared with the control
group.
ALP. Figure 3 shows the evolution of ALP activity for
MC3T3-E1 cells exposed to various concentrations of
zoledronate and titanium particles. For the sake of clarity,
the curves obtained with 10 µM and EDTA are not shown
because the 10 µM curve was very close to the 50 µM curve
while the EDTA curve was close to the 1 µM curve. In the
absence of titanium particles, the ALP activity of the cells
decreased with increasing concentration of zoledronate
(p < 0.0001) (Fig. 3a). Two patterns were observed. First
the control cells, those treated with 0.1 µM and 1 µM
zoledronate and those treated with EDTA, showed an
increase in ALP activity as compared with that at day 0.
This culminated after seven days before falling until day 28.
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Mean (SEM) ALP activity of MC3T3-E1 cells and at concentrations of zoledronate of 0,
0.1, 1.0, 10.0 and 50.0 µM a) without and b) with titanium particles.
Fig. 3a
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Secondly, the cells treated with 10 µM and 50 µM zole-
dronate showed a small increase after incubation for 48
hours before decreasing to low levels until day 28. In a
dose-dependent manner, the maximum ALP activity
decreased from 0.274 to 0.114 nM PNP/min/mg protein
when the cells were exposed to no zoledronate and 1 µM
zoledronate, respectively. When MC3T3-E1 cells were
exposed to titanium particles, the evolution of ALP activity
with time and concentration of zoledronate was very close
to that when no particles were present, apart from the max-
imum values which were two to five times lower than when
the particles were absent (p < 0.0001) (Fig. 3b). The largest
decrease in maximum ALP activity after adding particles
was for the control cells. The maximum ALP activity was
0.060 nM PNP/min/mg protein. No synergic effect of
zoledronate and particles on ALP activity was detected
(p < 0.01).
Discussion
Our study was performed to determine in vitro to which
concentration of zoledronate osteoblasts could be safely
exposed and to quantify the possible synergic effect of wear
particles and zoledronate on the proliferation and differen-
tiation of osteoblasts. This information is important in
regard to the development of an orthopaedic implant as a
drug-delivery system. Peri-implant bone resorption after
total hip arthroplasty has been shown to reach 14% during
the first three months after surgery.31 The presence of local
bisphosphonate is important for avoiding initial bone
resorption and instability of the implant. A recent in vivo
study has demonstrated the beneficial effect of local treat-
ment on stability.32 Even after a short duration in the body,
wear particles are created at the implant-bone interface. It
is therefore important to verify that there is no negative
synergic effect of particles and zoledronate on osteoblasts.
Few studies have been performed to determine in vitro
the effect of zoledronate on the behaviour of osteoblasts
while virtually no information is available when bisphos-
phonate and wear particles are present together. The effect
of zoledronate on proliferation was dependent on its con-
centration, with a clear cut-off concentration below which
the proliferation was the same as in the control group,
whereas above the cut-off concentration it was close to
zero.
The proliferation of osteoblasts treated with zoledronate
followed the same profile shown using other bisphospho-
nates.9,16,33 This observation was valid for both cell lines
which were used, human and murine. However, two differ-
ences were observed in the effect of zoledronate on both cell
lines. The first was the cut-off concentration which was 10
µM for murine osteoblasts and 1 µM for human osteoblasts.
This different sensitivity to concentration of the bisphos-
phonate has already been observed between mouse and
man with alendronate.34 The cut-off concentration of
zoledronate on the proliferation of human osteoblasts was
comparable to that obtained in a previous study.9 The
second difference was the temporal behaviour at 10 µM.
For human osteoblasts, the proliferation decreased after
seven days and stayed at a low level. By contrast for murine
osteoblasts exposed to 10 µM zoledronate it decreased from
day two but then recovered starting from day seven to
reach the control level at day 14. One explanation of this
recovery effect may be that proliferation is not suppressed
in the murine osteoblast but only slowed down. Cell divi-
sion during the experiment would result in the production
of more osteoblasts which would lead to a concentration of
zoledronate that could cross the cut-off level.
As has been shown by Farley et al,27 the ALP activity of
osteoblasts is inversely proportional to the amount of cal-
cium in the medium. Since zoledronate is known for its
ability to precipitate divalent metal ions such as calcium,
the concentration of calcium in the medium decreases with
increasing concentration of zoledronate. This explains the
decreasing ALP activity with increasing zoledronate
observed in our study. Moreover, this observation was sup-
ported by the result that treatment with EDTA, a known
chelating agent, induced a decrease in ALP activity. How-
ever, in vivo, this decreased calcium concentration in the
presence of zoledronate would probably be counter-
balanced by calcium homeostasis.
In previous studies, the effect of particles has given wide-
spread results, but in the main it has been shown that the
presence of particles stimulated bone resorption3,35,36 and
inhibited bone formation.17,19,20,37 Using the same titanium
particle concentration, similar results were obtained with
MG-63 cells.18
Im et al38 showed that the proliferation of osteoblasts
and ALP activity was increased when the cells were treated
with risedronate and etidronate. This difference in this
study may be related to the different bisphosphonate used
as well as the different concentrations. However, both stud-
ies showed that there was a bisphosphonate concentration
which did not impair cell activity. The lowered ALP activity
as a result of the presence of particles was significantly
stronger than the decrease to zoledronate. Lohmann et al21
suggested that the presence of particles either induced the
osteoblasts to stay in a less differentiated stage or slowed
down protein synthesis in general. They showed also that
most of the phagocytosed particles were located in the parts
of the cells involved in the assembling and packaging of
protein and not in the nucleus. This is supported by the fact
that we did not find any effects of the particles on the quan-
tities of mRNA isolated from MC3T3-E1 cells (data not
shown). Rodrigo et al39 concluded that post-transcriptional
events were influenced by the presence of particles.
In our study, the culture of osteoblasts with zoledronate
and titanium particles had neither a positive nor a negative
synergy on the behaviour of osteoblasts. We showed that
the presence of titanium particles decreased ALP activity
more than zoledronate at all concentrations of zoledronate.
In the case of a zoledronate-loaded coating or with systemic
zoledronate treatment after total hip arthroplasty, the pres-
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ence of zoledronate at a concentration lower than 1 µM
would not decrease the proliferation or affect the differen-
tiation of osteoblasts.
We conclude that zoledronate decreased proliferation at
concentration above 10 µM for MC3T3-E1 cells and above
1 µM for MG-63 cells. The presence of titanium particles
almost completely suppressed ALP activity, while zole-
dronate influenced the ALP activity in the absence of parti-
cles, probably through the chelation of calcium.
Importantly, no synergic effect of zoledronate and titanium
particles was observed on osteoblasts.
We wish to thank Arlette Kottelat (Laboratory for Orthopaedic Research) for
valuable laboratory work and Dr. J. R. Green (Novartis Pharma Research, Basel)
for the generous gift of zoledronate.
No benefits in any form have been received or will be received from a com-
mercial party related directly or indirectly to the subject of this article.
References
1. Herberts P, Malchau H, Garellick G. The Swedish National Hip Arthroplasty Reg-
ister, annual report 2002. Göteborg: Swedish Orthopaedic Association 2003.
2. Huiskes R. Finite element analysis of acetabular reconstruction: noncemented
threaded cups. Acta Orthop Scand 1987;58:620-5.
3. Goodman SB, Huie P, Song Y, et al. Loosening and osteolysis of cemented joint
arthroplasties: a biologic spectrum. Clin Orthop 1997;337:149-63.
4. Shanbhag AS, Hasselman CT, Rubash HE. Inhibition of wear debris mediated
osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997;344:33-43.
5. Elliott SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL. Alen-
dronate induces gastric injury and delays ulcer healing in rodents. Life Sci 1998;62:
77-91.
6. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates
for the treatment of bone resorption. Adv Drug Delivery Rev 2000;42:175-95.
7. Peter B, Pioletti DP, Terrier A, Rakotomanana LR. Orthopedic implant as drug
delivery system: a numerical approach. Comp Meth Biomech Biomed Eng 2001;4:
505-13.
8. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient. Vol.
1, Second ed. London: Parthenon Publishing Group, 1995:176.
9. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell pro-
liferation, differentiation, and gene expression in human osteoblasts. Cancer Res
2000;60:6001-7.
10. Garcia-Moreno C, Serrano S, Nacher M, et al. Effect of alendronate on cultured
normal human osteoblasts. Bone 1998;22:233-9.
11. Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T. Extracellular signal-regu-
lated kinases and calcium channels are involved in the proliferative effect of bispho-
sphonates on osteoblastic cells in vitro. J Bone Miner Res 2001;16:2050-6.
12. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new,
potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
13. Pan B, Farrugia AN, To LB, et al. The nitrogen-containing bisphosphonate,
zoledronic acid, influences RANKL expression in human osteoblast-like cells by acti-
vating TBF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-54.
14. Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different
bisphosphonates exert opposing effects on alkaline phosphatase and mineralization
in marrow osteoprogenitors. J Cell Biochem 1998;68:186-94.
15. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the matura-
tion of normal human osteoblasts. J Endocrinol Invest 2002;25:539-46.
16. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic
acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem
Biophys Res Commun 2002;291:680-6.
17. Yao J, Cs-Szabo G, Jacobs JJ, Kuettner KE, Glant TT. Suppression of osteoblast
function by titanium particles. J Bone Joint Surg [Am] 1997;79:107-12.
18. Pioletti DP, Takei H, Kwon SY, Wood D, Sung KL. The cytotoxic effect of titanium
particles phagocytosed by osteoblasts. J Biomed Mater Res 1999;46:399-407.
19. Vermes C, Glant TT, Hallab NJ, et al. The potential role of the osteoblast in the
development of periprosthetic osteolysis: review of in vitro osteoblast responses to
wear debris, corrosion products, and cytokines and growth factors. J Arthroplasty
2001;16(Suppl 1):95-100.
20. Zreiqat H, Crotti TN, Howlett CR, et al. Prosthetic particles modify the expression
of bone-related proteins by human osteoblastic cells in vitro. Biomaterials 2003;24:
337-46.
21. Lohmann CH, Bonewald LF, Sisk MA, et al. Maturation state determines the
response of osteogenic cells to surface roughness and 1,25-dihydroxyvitamin D3.
J Bone Miner Res 2000;15:1169-80.
22. Anderson GI, MacQuarrie R, Osinga C, et al. Inhibition of leukotriene function
can modulate particulate-induced changes in bone cell differentiation and activity.
J Biomed Mater Res 2001;58:406-14.
23. Sabokbar A, Fujikawa Y, Murray DW, Athanasou NA. Bisphosphonates in bone
cement inhibit PMMA particle induced bone resorption. Ann Rheum Dis 1998;57:
614-18.
24. Hyvonen PM, Kowolik MJ. Influence of dichloromethylene bisphosphonate on the
in vitro phagocytosis of hydroxyapatite particles by rate peritoneal exudate cells: an
electron microscopic and chemiluminescence study. Ann Rheum Dis 1992;51:203-9.
25. Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated
protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the
stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8.
26. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative
and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of
osteoblast development. J Bone Miner Res 1992;7:683-92.
27. Farley JR, Hall SL, Tanner MA, Wergedal JE. Specific activity of skeletal alkaline
phosphatase in human osteoblast-like cells regulated by phosphate, phosphate
esters, and phosphate analogs and release of alkaline phosphatases activity
inversely regulated by calcium. J Bone Miner Res 1994;9:497-508.
28. Pioletti DP, Leoni I, Genini D, et al. Gene expression analysis of osteoblastic cells
contacted by orthopaedic implant particles. J Biomed Mater Res 2002;61:408-20.
29. Pioletti DP, Kottelat A. The influence of wear particles in the expression of osteo-
clastogenesis factors by osteoblasts. Biomaterials 2004;25:5803-8.
30. Hakeda Y, Ikeda E, Kurihara N, et al. Induction of osteoblastic cell differentiation
by forskolin: stimulation of cyclic AMP production and alkaline phosphatase activity.
Biochim Biophys Acta 1985;838:49-53.
31. Venesmaa PK, Kroger, HP, Miettinen HJ, et al. Induction of osteoblastic cell dif-
ferentiation by forskolin: stimulation of cyclic AMP production and alkaline phos-
phatase activity. Biochim Biophys Acta 1985;838:49-53.
32. Peter B, Pioletti DP, Laib S, et al. Calcium phosphate drug delivery system: influ-
ence of local zoledronate release on bone implant osteointergration. Bone 2005;36:
52-60.
33. Giuliani N, Pedrazzoni M, Negri G, et al. Bisphosphonates stimulate formation of
osteoblast precursors and mineralized nodules in murine and human bone marrow
cultures in vitro and promote early osteoblastogenesis in young and aged mice in
vivo. Bone 1998;22:455-61.
34. Yamaguchi K, Motegi K, Iwakura Y, Endo Y. Involvement of interleukin-1 in the
inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 2000;130:
1646-54.
35. Takei H, Pioletti DP, Kwon SY, Sung KL. Combined effect of titanium particles and
TNF-alpha on the production of IL-6 by osteoblast-like cells. J Biomed Mater Res
2000;52:382-7.
36. Shanbhag AS, Macaulay W, Stefanovic-Racic M, Rubash HE. Nitric oxide
release by macrophages in response to particulate wear debris. J Biomed Mater Res
1998;41:497-503.
37. Pioletti DP, Rakotomanana LR. Can the increase of bone mineral density following
bisphosphonates treatments be explained by biomechanical considerations? Clin Bio-
mech 2004;19:170-4.
38. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation
and maturation by bisphosphonates. Biomaterials 2004;25:4105-15.
39. Rodrigo AM, Martinez ME, Escudero ML, et al. Influence of particle size in the
effect of polyethylene on human osteoblastic cells. Biomaterials 2001;22:755-62.
